MI Research

Nucleotron MIT is committed to the future of disease-specific tracers. We are focus in partner with pharmaceutical, biotech, and academic community in the development of new targeted molecular tracers employing our laboratory skills, state of the art equipment and high resolution PET/CT technology designed to provide accurate, specific, diagnostic information for physicians. In partnership with international pharmaceutical, biotechnical companies and equipment manufacturer, we are participating in research to improve the diagnosis and treatment of challenging multiples diseases.

Our research team participates in clinical research trials that capitalize on our PET/CT, and Nuclear Medicine expertise. Our experience in these advanced molecular imaging modalities—combined with our rigorous protocols and our relationship to the community makes Nucleotron MIT a sought-after partner for drug and device manufacturers as well as for contract research organizations (CROs).

The research team has participated in multiple clinical trials that use advanced imaging, from molecular diagnostics to dosimetry, and with partners like GE, Eli Lilly, Eisai, Merck, and many others. Our protocol includes standardization across multiple states, and reading workflows that ensure quality and continuous education.

We work together with physicians in the community to provide quality imaging for their clinical trials. We have experience in following protocols, contributing data, understanding research budgets, and performing high quality reads in advanced modalities. Physicians know that they are teaming with a well-developed research group that can play a valuable role in the imaging component of their clinical trials, and that we offer a familiar and comfortable local setting for their patients.